Surmodics

SRDX

ATLANTA, GA – – (Newsfile Corp. – January 23, 2023) – – Holzer & Holzer, LLC is investigating whether Surmodics, Inc. (“Surmodics” or the “Company”) (NASDAQ: SRDX) complied with federal securities laws. On January 19, 2023, the Company issued a press release regarding its premarket approval application (PMA) for SurVeil ™ stating: “the FDA indicated that the application is not currently approvable” and that “certain information within two general categories—biocompatibility and labeling—must be added by an amendment to the company’s PMA application to place it in approvable form.” Following that news, the Company’s stock dropped again.

If you purchased Surmodics stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at  cholzer@holzerlaw.com  or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at https://holzerlaw.com/case/surmodics/ to discuss your legal rights.

Registration Deadline

Lead Plaintiff Deadline Has Passed

Submit Your Information

View Representation Agreement

Submit Your Information

Name(Required)

First Last

Email(Required)

Phone(Required)

Address

Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country

Shares Purchased(Required)

Number of Shares Acquired

Acquisition Price Per Share

Shares Sold

Number of Shares Sold

Selling Price Per Share

By clicking on the button below, I am requesting Holzer & Holzer, LLC send me documents necessary to retain the firm.

I agree

Signed pursuant to the Uniform Electronic Transactions act as adopted by the various states and territories of the United States.

CAPTCHA